文献速递垂体与肾上腺疾病性腺与生殖内分泌

新型POR G88S突变导致严重PORD并确立关键药物基因组学风险特征

A Novel POR G88S Mutation Causes Severe PORD and Establishes a Critical Pharmacogenomic Risk Profile.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

在4个阿根廷家系5例患者中鉴定出纯合POR G88S突变,导致严重PORD伴性发育异常和肾上腺功能不全。体外研究显示该突变致蛋白不稳定和辅因子严重丢失,类固醇生成和药物代谢酶活性几乎丧失,确立“慢代谢者”表型。该突变是重要药物基因组学标志,在阿根廷反复出现提示可作为筛查靶点。

要点

  • POR G88S纯合突变导致严重PORD,表现为性发育异常和肾上腺功能障碍。
  • 该突变致蛋白不稳定,FMN丢失<30%、FAD丢失<15%,类固醇生成酶活性几乎消失。
  • 药物代谢酶活性严重受损(野生型的3%-9%),形成“慢代谢者”表型,需警惕药物风险。

核心结论

  • POR G88S突变导致所描述的最严重PORD类型之一,由动态蛋白不稳定和辅因子丢失驱动。
  • 该突变是关键的药物基因组学标志,在阿根廷反复出现提示可作为筛查靶点。

研究设计与样本

  • 翻译性研究,结合临床病例系列分析与新型蛋白变体的体外分子和功能表征。
  • 纳入4个无关阿根廷家系的5例患者(4例46,XY;1例46,XX),表现为性发育异常和肾上腺功能障碍。

主要发现

  • 所有患者均为c.262G>A(p.G88S)纯合突变。
  • 该FMN结合域变体导致蛋白不稳定,FMN辅因子丢失<30%,FAD丢失<15%。
  • 类固醇生成活性几乎废除:CYP21A2为野生型的1.3%,CYP17A1 17,20-裂解酶为5.5%。
  • 主要药物代谢酶活性严重受损,为野生型的3%-9%,确立“慢代谢者”表型。

临床怎么用

  • 对性发育异常和肾上腺功能障碍患者,尤其在阿根廷人群,应考虑POR G88S突变筛查。
  • 确诊PORD患者需评估药物代谢能力,警惕“慢代谢者”表型带来的用药风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: P450 oxidoreductase (POR) deficiency is a rare congenital adrenal hyperplasia with variable severity. The mechanisms of severe mutations and their full metabolic consequences, including drug metabolism, are not fully characterized. OBJECTIVE: To define the clinical, biochemical, and molecular consequences of a novel homozygous POR missense mutation, p.Gly88Ser (G88S), identified in 4 unrelated Argentine families. DESIGN: A translational study combining clinical case series analysis with comprehensive in vitro molecular and functional characterization of the novel protein variant. SETTING: Tertiary pediatric endocrine centers in Argentina and Switzerland. PATIENTS: We report 5 individuals (4 46,XY; 1 46,XX) from 4 unrelated families presenting with disorders of sex development and adrenal dysfunction. MAIN OUTCOME MEASURES: Clinical phenotypes, hormonal profiles, and POR gene sequencing. In vitro analysis of recombinant POR measured flavin content, reductase activity, and support of steroidogenic and drug-metabolizing P450s. RESULTS: All patients were homozygous for the c.262G>A (p.G88S) mutation. This FMN binding domain variant caused protein instability with severe loss of FMN (<30%) and FAD (<15%) cofactors. Steroidogenic activities were virtually abolished (CYP21A2: 1.3%; CYP17A1 17,20-lyase: 5.5% of wild-type), explaining the clinical phenotype. Activities of major drug-metabolizing enzymes were also severely impaired (3%-9% of wild-type), establishing a "poor metabolizer" phenotype. CONCLUSION: The POR G88S mutation causes one of the most severe forms of PORD described, driven by dynamic protein instability and cofactor loss. It is a critical pharmacogenomic marker, and its recurrence in Argentina suggests a potential screening target.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Rojas Velazquez MN, Lopez Dacal J, Jørgensen FS, et al. A Novel POR G88S Mutation Causes Severe PORD and Establishes a Critical Pharmacogenomic Risk Profile. J Clin Endocrinol Metab. 2026. PMID: 41258701. doi:10.1210/clinem/dgaf630

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。